The CERN-MEDICIS (MEDical Isotopes Collected from ISolde) facility has delivered its first
radioactive ion beam at CERN (Switzerland) in December 2017 to support the research and …

Thulium-167 is a promising radionuclide for nuclear medicine applications with potential use
for both diagnosis and therapy (“theragnostics”) in disseminated tumor cells and small …

Samarium-153 (153Sm) is a highly interesting radionuclide within the field of targeted
radionuclide therapy because of its favorable decay characteristics. 153Sm has a half-life of …

In recent years, radiopharmaceuticals have been increasingly used for diagnostics and
treatment of cancer. In addition to a biological vector, a modern radiopharmaceutical …

Terbium (Tb) is a promising element for the theranostic approach in nuclear medicine. The
new CERN-MEDICIS facility aims for production of its medical radioisotopes to support …

Terbium-155 has been identified for its potential for single-photon emission computed
tomography (SPECT) in nuclear medicine. For activity measurements, an accurate and …

An increasing number of radiopharmaceuticals and proteins are available for diagnosing
and treating various diseases. The demand for existing and newly developed …

This work presents the production cross-sections of Ce, Tb and Dy radionuclides produced
by 300 MeV to 1.7 GeV proton-induced spallation reactions in thin tantalum targets as well …

Abstract The radionuclide 149 Tb (t 1/2= 4.1 h) is a potential theranostic isotope which can
simultaneously be used for targeted-alpha-particle therapy and positron-emission …

The terbium (Tb) family has attracted much attention in recent years thanks to the diagnostic
and therapeutic applications of the quadruplet 149 Tb, 152 Tb, 155 Tb and 161 Tb …